Pacira | PCRX - Cash And Equivalent


Pacira reported $158.54M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Assertio Holdings USD 38.5M 8.59M Sep/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cara Therapeutics USD 21.42M 770K Sep/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 158.54M 10.96M Dec/2025
Perrigo USD 432.1M 22.1M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xeris Pharmaceuticals USD 111.04M 19.44M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024
Zoetis USD 2.08B 649M Sep/2025